Home
About
FAQ
History (17)
Apolipoprotein E3
Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.
MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis.
Mongraw-Chaffin, Morgana
Rudnick, Sean
See All 17 Pages
Find People
Find Everything
Edit My Profile
My Person List (
0
)
Return to Top
Login
Username
Password